Esperion Therapeutis.Inc. buy Bankster
Summary
This prediction ended on 03.04.23 with a price of €1.43. Massive losses of -65.91% were the result for the BUY prediction by Bankster. Bankster has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -8.967% | -8.967% | 41.152% |
iShares Core DAX® | 1.662% | 4.835% | 17.361% |
iShares Nasdaq 100 | 0.667% | 0.000% | 38.234% |
iShares Nikkei 225® | -2.139% | -4.786% | 13.099% |
iShares S&P 500 | 0.564% | 0.775% | 29.181% |
Comments by Bankster for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Bankster for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
25.03.24
25.03.25
29.03.24